- Home
- DNTH vs PCVX Comparison
DNTH vs PCVX Comparison
Compare DNTH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | PCVX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DNTH | PCVX |
|---|---|---|
| Price | $106.95 | $59.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $121.00 | $88.25 |
| AVG Volume (30 Days) | 544.6K | ★ 927.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,036,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.28 | $30.81 |
| 52 Week High | $117.88 | $65.00 |
Technical Indicators
Market Signals| Indicator | DNTH | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 47.74 |
| Support Level | $101.19 | $58.51 |
| Resistance Level | $107.99 | $63.39 |
| Average True Range (ATR) | 4.59 | 2.10 |
| MACD | -0.85 | -0.39 |
| Stochastic Oscillator | 26.26 | 10.69 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.